Private Market View

Zhifeng Pharmaceutical

Jinhua, China · Founded 2025 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include Hangzhou Puhua Tianji Investment, Silicon Valley Real Stone Asset Management, ZJKF Capital Management, Zhejiang Dajing Development Investment.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 4 names
  • ·Watchlist + deal alerts for Zhifeng Pharmaceutical
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Zhifeng Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Zhifeng Pharmaceutical

Manufacturer of medical technology and biopharmaceutical research intended to advance clinical development and healthcare innovation. The company offers expertise in experimental medicine, biochemistry research, and medical device distribution, enabling healthcare institutions and research organizations to access advanced therapeutic technologies and improved patient care.

Sector
Healthcare
HQ
Jinhua, China
Founded
2025
Ownership
Privately Held (backing)
PA Mark — not yet priced

Zhifeng Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Zhifeng Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Zhifeng Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.